Movement Alert|Ecolab Rises 4.19% in Regular Trading, UBS Upgrades Rating to Buy with Higher Target Price

Market Focus
May 28

On May 28, Ecolab rose 4.19% in regular trading, trading at $265.035/share, with trading volume of $261 million.

On the news front, UBS upgraded Ecolab from Neutral to Buy and raised its target price from $293 to $325. Previously, Jefferies also maintained a Buy rating with a target price of $345. According to FactSet, the average analyst rating for Ecolab is Overweight, with a mean target price of $320.89, implying approximately 21% upside from recent levels.

The upgrade follows investor meetings where management highlighted expectations for revenue growth to accelerate to 5%-7% over the medium term, supported by high-growth areas including life sciences, global high-tech, pest control, and digital solutions. Recent price increases, including temporary energy-related fees and longer-lasting list-price adjustments, are expected to offset higher commodity costs by late Q2 or early Q3, supporting margin improvement.

Ecolab is a global sustainability leader providing water, hygiene, and infection prevention solutions across food, healthcare, life sciences, hospitality, and industrial markets.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10